Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATXN2 | Q99700 | 10/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 9/20 | 0.48 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24793630 | 1.00 | ATXN2 (0.48) | ATXN2ENPP2GPR183SCD5 | |
| SCHEMBL29709766 | 0.93 | ENPP2 (0.45) | ATXN2ENPP2 | |
| SCHEMBL24794739 | 0.93 | ENPP2 (0.45) | ATXN2ENPP2 | |
| SCHEMBL24793643 | 0.92 | ATXN2 (0.50) | ATXN2ENPP2 | |
| SCHEMBL24794177 | 0.88 | ALDH1A1 (0.50) | — | |
| SCHEMBL23121996 | 0.84 | ENPP2 (0.48) | ATXN2ENPP2 | |
| SCHEMBL24792954 | 0.82 | NR1H2 (0.40) | ATXN2ENPP2 | |
| SCHEMBL24792914 | 0.81 | CREBBP (0.41) | ATXN2 | |
| SCHEMBL29709817 | 0.81 | CREBBP (0.41) | ATXN2 | |
| SCHEMBL24794728 | 0.81 | NR1H2 (0.42) | ATXN2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402901-A1 | SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | BIAL R&D INVEST S A (PT) | 2022-12-22 | — | — | US | disclosed |
| EP-4031535-A1 | SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | Bial-R&D Investments, S.A. (PT) | 2022-07-27 | — | — | EP | disclosed |
| CN-114761386-A | Substituted N-heterocyclic carboxamides as acid ceramidase inhibitors and their use as pharmaceuticals | 比亚尔R&D投资股份公司 | 2022-07-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402901-A1 | SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | ASAH2, ASAH1, GBA1 | ATXN2 574/4885ENPP2 48/4885GPR183 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.